NCT07366411

taVNS on Functional Mobility in People With DP

Not yet recruiting Phase 2 Last updated 26 January 2026

What this trial tests

Phase 2 trial testing Active taVNS in PARKINSON DISEASE (Disorder) in 30 participants. Not yet recruiting.

Timeline

15 February 2026

Primary endpoint
15 March 2027

30 June 2027

Quick facts

Lead sponsor	Universidade Federal de Pernambuco
Phase	Phase 2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	30
Start date	15 February 2026
Primary completion	15 March 2027
Estimated completion	30 June 2027
Sites	1 location across Brazil

Drugs / interventions tested

• Active taVNS
• Sham taVNS

Conditions studied

• PARKINSON DISEASE (Disorder) — all drugs for PARKINSON DISEASE (Disorder) →

Sponsor

Universidade Federal de Pernambuco — full company profile →

Who can join

Adults 40 to 80, any sex, with PARKINSON DISEASE (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Parkinson's disease (PD) is characterized by motor impairments such as bradykinesia accompanied by resting tremor and/or rigidity. As PD progresses due to its neurodegenerative nature, complementary strategies must be developed to optimize its effects. Transcutaneous auricular vagus nerve stimulation (taVNS) has emerged as a strategy for controlling the symptoms of the disease. Nevertheless, the efficacy of this approach in managing PD remains to be elucidated. The objective of the present study is to investigate and compare the effects of transcutaneous vagus nerve stimulation (taVNS) and sham taVNS on functional mobility, which is the primary outcome and will be assessed using the Timed Up and Go test. The following tests will be used to evaluate the secondary outcomes: the miniBESTest and the Biodex Balance System (balance), the MDS-UPDRS and the Five-Time Sit-to-Stand Test (motor function), the FOG-Q (freezing of gait), the 10-Meter Walk Test (gait speed), the PGIC (perception of change), and the recording of adverse events. The volunteers will be divided into two groups: one group will receive taVNS in conjunction with physical therapy, while the other group will receive a sham taVNS in conjunction with physical therapy. To assess the effect of therapy, the efficacy of taVNS in enhancing the effects of physical therapy on the functional mobility of people with PD will be evaluated.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.